Reuters logo
BRIEF-CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia
December 7, 2017 / 12:22 PM / in 3 days

BRIEF-CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia

Dec 7 (Reuters) - Crispr Therapeutics Ag:

* CRISPR THERAPEUTICS SUBMITS FIRST CLINICAL TRIAL APPLICATION FOR A CRISPR GENE-EDITED THERAPY, CTX001 IN Β-THALASSEMIA

* CRISPR THERAPEUTICS AG - ANNOUNCED SUBMISSION OF A CLINICAL TRIAL APPLICATION FOR CTX001 IN Β-THALASSEMIA

* CRISPR THERAPEUTICS AG - PHASE 1/2 TRIAL OF CTX001 IS EXPECTED TO BEGIN IN EUROPE IN 2018

* CRISPR THERAPEUTICS AG - CO ALSO PLANS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 TO TREAT SICKLE CELL DISEASE WITH U.S. FDA IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below